Expertise in
16
conditions

Dr. Kellie Sprague

Hematology
Mainehealth Cancer Care
265 Western Ave Ste 2, 
South Portland, ME 
32 Years of Experience
Expertise in
16
conditions
Mainehealth Cancer Care
265 Western Ave Ste 2, 
South Portland, ME 

Overview

Kellie Sprague is a Hematologist in South Portland, Maine. Dr. Sprague has been practicing medicine for over 32 years is highly rated in 16 conditions, according to our data. Her top areas of expertise are Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in MA

Hospital Affiliations

Mainehealth Stephens Hospital
Mainehealth Maine Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Mainehealth Cancer Care
265 Western Ave Ste 2, South Portland, ME 04106
Other Locations
Tufts Medical Center
800 Washington St, Boston, MA 02111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Enrollment Status: Terminated
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Enrollment Status: Completed
Publish Date: July 19, 2018
Intervention Type: Other
View 7 Less Clinical Trials

10 Total Publications

Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.
Journal: Transfusion
Published: January 03, 2020
Similar Doctors
Expertise in
48
conditions
Dr. John Winters
Hematology
Expertise in
48
conditions
Dr. John Winters
Hematology

New England Cancer Specialists - Rock Row

11 Rock Row Ste 120, 
Westbrook, ME 
 (5.0 miles away)
207-303-3300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Winters is a Hematologist in Westbrook, Maine. Dr. Winters is highly rated in 48 conditions, according to our data. His top areas of expertise are Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Melanoma, and Bone Marrow Aspiration.

Expertise in
10
conditions
Dr. Jessica Bian
Hematology
Expertise in
10
conditions
Dr. Jessica Bian
Hematology

Mainehealth Cancer Care

265 Western Ave Ste 2, 
South Portland, ME 
 (2.0 miles away)
207-661-0200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jessica Bian is a Hematologist in South Portland, Maine. Dr. Bian is highly rated in 10 conditions, according to our data. Her top areas of expertise are Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, and Bone Marrow Aspiration.

Expertise in
33
conditions
Dr. Na Liu
Hematology
Expertise in
33
conditions
Dr. Na Liu
Hematology

St. Mary's Regional Medical Center

93 Campus Ave, 
Lewiston, ME 
 (32.6 miles away)
207-777-4420
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Na Liu is a Hematologist in Lewiston, Maine. Dr. Liu is highly rated in 33 conditions, according to our data. Her top areas of expertise are Chronic T-Cell Leukemia (CTCL), Adult T-Cell Leukemia, Metastatic Insulinoma, and Pancreatic Islet Cell Tumor.

Frequently Asked Questions about Dr. Kellie Sprague

How do I make an appointment with Dr. Kellie Sprague?

You can book an appointment with Dr. Kellie Sprague by calling their office at 207-661-0200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kellie Sprague a top-rated expert for Acute Promyelocytic Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kellie Sprague is classified as an Distinguished expert for Acute Promyelocytic Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kellie Sprague specialize in?

While Dr. Kellie Sprague is a Hematology, they have specific expertise in Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kellie Sprague participate in research or clinical trials?

Yes. Dr. Kellie Sprague has published 10 articles and abstracts on conditions like Acute Promyelocytic Leukemia. You can view a list of Dr. Kellie Sprague's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kellie Sprague accept my insurance?

Dr. Kellie Sprague accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 207-661-0200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sprague's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile